Q2041
HCPCSAxicabtagene ciloleucel car+
Official HCPCS Level II long descriptor
Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
HCPCS Level II code Q2041 is maintained by CMS and is active in the current quarterly release.
Short descriptor
Axicabtagene ciloleucel car+
Added to HCPCS: 2018-04-01
Nearby codes in Q2
- Q2026Radiesse injection
- Q2028Inj, sculptra, 0.5mg
- Q2034Agriflu vaccine
- Q2035Afluria vacc, 3 yrs & >, im
- Q2036Flulaval vacc, 3 yrs & >, im
- Q2037Fluvirin vacc, 3 yrs & >, im
- Q2038Fluzone vacc, 3 yrs & >, im
- Q2039Influenza virus vaccine, nos
- Q2042Tisagenlecleucel car-pos t
- Q2043Sipuleucel-t auto cd54+
- Q2049Imported lipodox inj
- Q2050Doxorubicin inj 10mg
- Q2052Home ivig, services/supplies
- Q2053Brexucabtagene car pos t
- Q2054Lisocabtagene mara car pos t
- Q2055Idecabtagene vicleucel car
Where this code sits
Krasyn AI Coder
Get code suggestions automatically as you type notes. Free for 50 analyses.
Install for Chrome — freeSource
HCPCS Level II July 2026 quarterly update. Centers for Medicare & Medicaid Services (CMS), “July 2026 Alpha-Numeric HCPCS File” (HCPC2026_JUL_ANWEB_06172026.txt). Download the original file from cms.gov. Public domain (US Government work). Descriptors, billable flags and instructional notes on this page are reproduced from that file without modification. Krasyn adds no clinical guidance.